Incyte SEC filings, summarized
We read every Incyte 8-K filing and insider trade the night it hits SEC EDGAR, and turn it into a two-minute plain-English summary.
Track INCY in your inbox
Add Incyte to your watchlist — free, every morning.
Recent filings
Incyte R&D chief sells $2.8M in stock
Pablo J. Cagnoni, Incyte’s President and Global Head of R&D, sold 9,233 shares at $120.50 each for approximately $1.11 million and 13,985 shares at $120.49…
Incyte Reaches CMS Agreement on Medicaid Pricing for Jakafi and Jakafi XR
Incyte said on August 31, 2026, that it entered an agreement with the Centers for Medicare & Medicaid Services to give state Medicaid programs access to…
Incyte R&D chief sells $1.36 million in stock
Pablo J. Cagnoni, Incyte Corp.’s President and Global Head of R&D, sold 10,801 shares of common stock on Aug. 19 at $125.56 per share, for approximately…
Incyte R&D chief sells 10,803 shares for about $1.3 million
Pablo J. Cagnoni, Incyte’s President and Global Head of R&D, sold 10,803 common shares on Aug. 12 at $120.04 per share, for approximately $1,296,792. He…
Incyte R&D head sells $1.3M in stock
Pablo J. Cagnoni, Incyte’s President and Global Head of R&D, sold 10,640 shares of common stock at $122.69 per share on Aug. 5, 2026. The transaction was…
Incyte EVP Patrick Mayes sells $5.7M in stock
Incyte EVP and Chief Scientific Officer Patrick A. Mayes sold 47,954 shares in open-market transactions on July 31 and August 3 at prices ranging from…
Incyte R&D chief sells $1.9 million in stock
Pablo J. Cagnoni, Incyte Corp.’s President and Global Head of R&D, sold 15,888 shares of common stock on July 31 at $119.70 per share, for approximately…
Incyte reports Q2 revenue growth and raises 2026 sales guidance
Incyte reported second-quarter 2026 revenue of $1.67 billion, up 38% year over year, and net income of $585.6 million, or $2.81 diluted EPS; net sales rose…
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and…
Incyte ($INCY) filed an 8‑K (Item 9.01) furnishing a press release dated Mar 25, 2026 (Exhibit 99.1) and an Interactive XBRL cover page (Exhibit 104).…
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J.
Effective Mar 25, 2026, Incyte announced exec title changes: Pablo J. Cagnoni → President, Incyte & Global Head of R&D; Steven H. Stein → EVP, Chief Medical…
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg…
FDA issued a Complete Response Letter on Feb 27, 2026 for the sBLA for Zynyz® (retifanlimab‑dlwr) 375mg for metastatic NSCLC + platinum chemo. CRL cites…
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page…
Incyte files Form 8‑K (Item 9.01) dated Feb 10, 2026 to furnish a press release (Exhibit 99.1); Cover Page Interactive XBRL also filed (Exhibit 104). $INCY…
Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY…
Incyte ($INCY) on Feb 10, 2026 filed an 8‑K (Item 2.02) and issued a press release announcing Q4 and FY 2025 financial results for the period ended Dec 31,…
Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025.
Hervé Hoppenot retires from Incyte's Board effective Dec 10, 2025. Former Chairman & CEO; board member since 2014. 8‑K shows no replacement named. $INCY 👋…